Form 4: FIL Ltd Reports Conversion of Preferred Shares to Common Stock in Bicara Therapeutics Following IPO

FIL Ltd reports the conversion of Series Seed, B, and C Preferred Shares to Common Stock in Bicara Therapeutics (BCAX) following the completion of the company's initial public offering.

Summary

• FIL Ltd, through its related entities, reported the conversion of preferred shares into common stock of Bicara Therapeutics Inc. (BCAX) on September 16, 2024, following the company's IPO.
• Series Seed, B, and C Preferred Shares converted on a 1-for-1 basis into shares of Common Stock.
• 54,092 Series Seed Preferred Shares were converted.
• 606,885 Series B Preferred Shares were converted.
• 352,876 Series C Preferred Shares were converted.
• After the conversion, Eight Roads Ventures India Healthcare IV, L.P. indirectly holds 1,013,853 shares of common stock.

Sentiment

Score: 7

Explanation: The document reflects a standard post-IPO conversion of shares, which is generally a neutral to slightly positive event as it simplifies the company's capital structure.

Positives

• The conversion of preferred shares to common stock simplifies the capital structure of Bicara Therapeutics following its IPO.

Future Outlook

The document does not contain any specific forward-looking statements regarding Bicara Therapeutics' future performance.

Industry Context

This announcement is typical following an IPO, as preferred shares held by early investors are often converted to common stock, aligning their interests with public shareholders.

Stakeholder Impact

• The conversion of preferred shares to common stock may have a slight impact on the ownership structure of Bicara Therapeutics.

Key Dates